Skip to content
Peptigraph home

Is Tesamorelin Legal? FDA, Compounding and WADA Status

Tesamorelin's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
FDA status
Approved (Egrifta)
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Prohibited (S2.2.4)
In and out of competition
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

Current status

FDA approved (Egrifta)

Tesamorelin is FDA approved (Egrifta). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

Tesamorelin: regulatory status by country
CountryStatusSource
United StatesApprovedApproved by FDA as Egrifta (original approval 10 Nov 2010), Theratechnologies, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (label quote).api.fda.govchecked 2 Oct 2026

Timeline

  1. FDA warning letters to five research-peptide sellersEnforcement
Every peptide on the FDA tracker

Compounding and research-use sellers

  • Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
  • The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
  • "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.

Sport and drug testing

Prohibited by WADA (S2.2.4)

Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.

Outside the US

Rules differ by country. What each regulator's own records show, with the date we checked:

Tesamorelin: regulatory status by country
CountryStatusSource
United KingdomNo approved product foundNo approved product found in an emc (UK SmPC compendium) search for "tesamorelin" on 2 Oct 2026.medicines.org.ukchecked 2 Oct 2026
CanadaNot marketedHealth Canada DPD lists Egrifta (tesamorelin) with status Cancelled Post Market, i.e. not currently marketed.health-products.canada.cachecked 2 Oct 2026
AustraliaNo approved product foundNo approved product found in an ARTG search for "tesamorelin" on 2 Oct 2026.tga.gov.auchecked 2 Oct 2026
European UnionApplication withdrawnEMA lists Egrifta (tesamorelin) with status Application withdrawn; no centrally authorised tesamorelin product.ema.europa.euchecked 2 Oct 2026

Approved for one condition, as a biologic application

Egrifta’s FDA label indication is narrow: reducing excess abdominal fat in HIV-infected adults with lipodystrophy, with a stated limit that long-term cardiovascular safety has not been established.[8]

Drugs@FDA files tesamorelin under a BLA, the biologics application type, with an original approval date of 20101110.[2]

The label describes tesamorelin as comprising the 44 amino acid sequence of human growth hormone-releasing factor.[8]

FDA's final rule defines a protein as an amino acid polymer greater than 40 amino acids; tesamorelin's sequence, per the label above, is longer than that.[9]

Where tesamorelin is not on the market

Health Canada's database lists Egrifta with the status Cancelled Post Market.[4]

The EMA record for Egrifta lists the status Application withdrawn.[6]

The Australian register search for tesamorelin returned no matching results.[5]

Where FDA took action in 2026

Tesamorelin sold as a research peptide appears in FDA’s August warning letters: one letter lists “Tesamorelin Research Peptide” and a tesamorelin-ipamorelin blend among products it calls unapproved new drugs.[10]

In its August letter FDA quoted a seller's statement that research indicates tesamorelin may enhance cognitive function. The approved indication is abdominal fat reduction in HIV-infected adults with lipodystrophy.[10]

The letter described a "peptide calculator" sold beside bacteriostatic water as a resource that provides the means to prepare an injectable drug for human administration.[10]

Sport

WADA lists tesamorelin by name in S2.2.4 among growth-hormone-releasing hormone analogues, prohibited at all times.[1]

Common questions

Is tesamorelin FDA approved?

Yes, as Egrifta from Theratechnologies, for excess abdominal fat in HIV-infected adults with lipodystrophy.[2]

Is Tesamorelin legal to buy?

As an approved drug it requires a prescription in the US. Products sold online as research chemicals "not for human use" are not the approved drug.

Is Tesamorelin banned by WADA?

Yes. Prohibited by WADA (S2.2.4), in and out of competition.

Is tesamorelin legal?

As prescribed Egrifta it is an approved drug in the US. Sold as a “research” product for human injection it falls in the category FDA’s August letters call unapproved new drugs.[10]

Tesamorelin FDA approval: what is the date?

The Drugs@FDA record gives an original approval date of 20101110 for Egrifta.[2]

Is tesamorelin banned in sports?

Yes. It is named in S2.2.4 and prohibited at all times.[1]

More on Tesamorelin

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Approved by FDA as Egrifta (original approval 10 Nov 2010), Theratechnologies, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "tesamorelin" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  4. 4Canada: Health Canada DPD lists Egrifta (tesamorelin) with status Cancelled Post Market, i.e. not currently marketed.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
  5. 5Australia: No approved product found in an ARTG search for "tesamorelin" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
  6. 6European Union: EMA lists Egrifta (tesamorelin) with status Application withdrawn; no centrally authorised tesamorelin product.European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
  7. 7FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  8. 8EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  9. 9Official web pageOfficial web page · web page
  10. 10Official web pageOfficial web page · web page

Found an error? Report a correction.